MAPK7 and T-cell non-Hodgkin lymphoma: The delayed death due to T-cell lymphoma development in Atm−/−; Erk5−/− mice suggests that pharmacological targeting of ERK5 has therapeutic potential for T-cell lymphoma patients carrying inactivating ATM mutations [70].